30 Jan 2023 • According to a recent STEP study, semaglutide 2.4 mg improves both short- and long-term control of eating in persons who are obese or overweight. Semaglutide 2.4 mg, compared to a placebo, enhanced individuals' capacity to control their eating over a longer period of 104 weeks, making it simpler to resist food cravings. By enhancing the control of eating and food cravings, Semaglutide 2.4 mg may be an effective longer-term treatment for obese/overweight individuals, enabling patients to successfully lose and maintain a significant amount of weight. Semaglutide 2.4 mg, a once-weekly subcutaneous injection of glucagon-like peptide-1 receptor agonist, has been approved as an adjunctive treatment for maintaining and achieving weight loss in overweight/obese individuals. Semaglutide has been shown in prior research to be helpful in reducing body weight and to have short-term positive effects on the regulation of eating elements such as fullness and hunger, food cravings, and mood in overweight/obese individuals. Semaglutide improves both short- and long-term control of eating, as shown by this study, where patients reported less hunger, fewer cravings, and greater feelings of fullness. Semaglutide also stops the compensatory increase in the appetite that would often be anticipated after significant weight loss. The significant and long-lasting effects of weight loss reported with once-weekly Semaglutide 2.4 mg are most likely the result of these factors taken together.

Source: Medical Dialogues | Read full story